TN 401
Alternative Names: TN-401Latest Information Update: 02 Dec 2024
Price :
$50 *
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Plakophilin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cardiomyopathies
Most Recent Events
- 25 Nov 2024 Phase-I clinical trials in Cardiomyopathies in United Kingdom (IV)
- 01 Oct 2024 Tenaya Therapeutics has patent protection for method of treating an arrhythmogenic right ventricular cardiomyopathy (ARVC) with an AAV9 virion encoding the PKP2 protein in USA
- 08 Aug 2024 Tenaya receives clearance of Clinical Trial Application by the UK's Medicines and Healthcare Products Regulatory Agency for phase I trial for TN 401 in Cardiomyopathies